Ganga Pharmaceuticals Limited

Equities

539680

INE615T01017

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:55 24/06/2024 BST 5-day change 1st Jan Change
24.67 INR -.--% Intraday chart for Ganga Pharmaceuticals Limited -.--% -13.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp CI
Ganga Pharmaceuticals Limited announced that it expects to receive INR 21 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp CI
Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds MT
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020 CI
Ganga Pharmaceuticals Limited Announces Management Changes CI
Ganga Pharmaceuticals Limited Announces the Appointment and Re-Designation of Sanjay Kulkarni as Executive Director CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019 CI
874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019. CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2018 CI
Ganga Pharmaceuticals Limited Appoints Anagh B. Sharma as Chief Financial Officer CI
Ganga Pharmaceuticals Limited Announces Resignation of Ganesh Jyothimani Paradeshi, Chief Financial Officer CI
Ganga Pharmaceuticals Limited Announces Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2018 CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2017 CI
Ganga Pharmaceuticals Limited Reports Audited Earnings Results for Fourth Quarter and Full Year Ended March 31, 2017 CI
2,106,950 equity of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2017. CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2016 CI
Ganga Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2016 CI
Ganga Pharmaceuticals Limited Appoints Priti Kothari Bhaiya as Company Secretary and Compliance Officer to Replace Mustafa Shabbir Badami CI
Chart Ganga Pharmaceuticals Limited
More charts
Ganga Pharmaceuticals Limited is an India-based company, which is engaged in the production of ayurvedic medicines. The Company is also into marketing and distribution of ayurvedic medicines. It offers ayurvedic medicines in various categories, including acidity, antidandruff, antioxidants, blood purifier and skin disorder, constipation, cough and cold, dental care, diarrhea, ear care, female tonic, hair care, hemorrhoids and piles, indigestion, iron tonic, joint pains, kidney stone, liver disorder, rejuvenation tonic, sleep inducers, and herbal cosmetics. Its products include Asuka tablets, Dendroil, Ashwo tablets - tonic for body and mind, Raktaj tablets/syrup - for skin disorders, Nirmalaya (proprietary) - relieves constipation, Khadira tablets (80 mg.) (A.S.S) - relieves cough, Danta Doshahar Manjan - gum and teeth protective, Holetrica capsule - checks diarrhea and corrects digestion, Karnaraj drops (proprietary) - ear drops, Femoherb syrup/tablets, and Mahabhrungraj oil.
More about the company
  1. Stock Market
  2. Equities
  3. 539680 Stock
  4. News Ganga Pharmaceuticals Limited
  5. Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds